Get started
Author

Nagendra Ramanjinappa

Observed name: N. Ramanjinappa
Institution: Viatris
Observed institutions: Mylan (India), Viatris
ORCID: 0000-0003-2717-3772
Observed ORCID: 0000-0003-2717-3772
OpenAlex ID: A5027288877
Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science
2023 · James F Donohue, J Stuart Elborn, et al. · Journal of Healthcare Leadership · 58
Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists
2021 · Suresh H. Advani, D. C. Doval, et al. · Indian Journal of Gynecologic Oncology · 4
PDF
Shifting trends in the usage of trastuzumab with its biosimilar inception in India.
2023 · Nagendra Ramanjinappa, Kunvar Harsh Upveja, et al. · Journal of Clinical Oncology · 1
The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective
2022 · Mohan Bajranglal Agarwal, Manthanathu Joseph John, et al. · Indian Journal of Medical and Paediatric Oncology · 1
PDF
20P Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
2022 · N. Ramanjinappa, J. Agarwal, et al. · Annals of Oncology
PDF
Works count: 5
Citation count: 64
H-index: 2
I10-index: 1
Year
Topic
Type